Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > GLP-1 Receptor Agonist Market

GLP-1 Receptor Agonist Market Share

Report ID: GMI5864
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

GLP-1 Receptor Agonist Market Share

Companies such as Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi dominate this market due to their strong research capabilities, innovative drug formulations, and commitment to addressing diabetes and obesity challenges. These leaders continually invest in developing advanced GLP-1 receptor agonist products to meet the growing demand for effective and patient-friendly diabetes solutions.

GLP-1 Receptor Agonist Market Companies

The competitive landscape of the GLP-1 receptor agonist industry includes Boehringer Ingelheim International GmbH

Eli Lilly and Company
Sanofi
Novo-Nordisk A/S
AstraZeneca
Pfizer.Inc
Amgen, Inc.
Innovent Biologics, Inc.
PegBio Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Boehringer Ingelheim International GmbH

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global GLP-1 receptor agonist industry was valued at USD 24.4 billion in 2023 and is expected to grow at a 9.7% CAGR from 2024 to 2032, driven by rising incidences of type 2 diabetes and obesity globally.

he semaglutide segment held a dominant market share in 2023 and is projected to sustain growth through 2032 due to its efficacy in controlling blood sugar levels and promoting weight loss.

North America held the largest share of the GLP-1 receptor agonist market in 2022 and is projected to grow at a robust CAGR through 2032, driven by a high prevalence of diabetes, increasing obesity rates, and a well-established healthcare infrastructure.

Key players in the market include Boehringer Ingelheim International GmbH, Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Innovent Biologics, Inc., and PegBio Co., Ltd.